Treatment of Guillain‐Barré syndrome with high‐dose gammaglobulin

Publisher Website
Google Scholar
Abstract
Intravenous gammaglobulin (IVGG) can improve the clinical course of several immune-mediated diseases. We report the first results of such treatment in eight patients with severe Guillain-Barré syndrome (GBS). We observed that IVGG was beneficial in at least some of the patients with severe GBS. These results should be confirmed in a randomized trial.